WHO Introduces Helminth Drug Initiative With Special Supplement
Helminth infections are responsible for a huge health burden on developing country populations, and the number of drugs available to treat them is incredibly limited.
The paucity of products in development for helminth diseases has necessitated a focused initiative to boost the R&D pipeline for these diseases. Consultation meetings organised by the WHO Research and Training in Tropical Diseases (TDR) Programme in collaboration with the Japanese Society of Parasitology led to the establishment of the Helminth Drug Initiative (HDI), which aims to facilitate R&D against human parasitic worm infections.
In a freely available 103-page peer-reviewed special issue of Expert Opinion on Drug Discovery, the rationale behind the HDI is documented, as well as reports of technical consultations and recommendations that led to the initial establishment of the Initiative within TDR.
"The Helminth Drug Initiative is an integral part of an innovative drug discovery platform established by TDR based on a coordinated network of partners from industry and academia from the developed and developing countries ", commented Dr Solomon Nwaka, who leads drug discovery efforts and the HDI.
The special issue focusing on the Helminth Drug Initiative of the Expert Opinion on Drug Discovery is available for free download at www.pjbpubs.com.
The Expert Opinion series provides systematic and authoritative reviews to support every stage of the drug discovery and R&D pipeline from target to market. Each of the eleven journals in the series covers a specific aspect of the pharmaceutical pipeline.
The series contains the following journals: Expert Opinion on Biological Therapy, Expert Opinion on Drug Delivery, Expert Opinion on Drug Discovery, Expert Opinion on Drug Metabolism & Toxicology, Expert Opinion on Drug Safety, Expert Opinion on Emerging Drugs, Expert Opinion on Investigational Drugs, Expert Opinion on Medical Diagnostics, Expert Opinion on Pharmacotherapy, Expert Opinion on Therapeutic Patents, and Expert Opinion on Therapeutic Targets.